Psyence Biomed Advances Phase IIb Psilocybin Trial for Cancer Patients, Patient Screening Begins - StockTitan
| PBMWW Stock | 0.02 0 4.74% |
Slightly above 52% of Psyence Biomedical's sophisticated investors are presently thinking to get in. The analysis of overall sentiment of trading Psyence Biomedical Ltd stock suggests that some investors are interested at this time. Psyence Biomedical's investing sentiment can be driven by a variety of factors including economic data, Psyence Biomedical's earnings reports, geopolitical events, and overall market trends.
Psyence |
Psyence Biomed Advances Phase IIb Psilocybin Trial for Cancer Patients, Patient Screening Begins StockTitan
Read at news.google.com
 |
Psyence Biomedical Fundamental Analysis
We analyze Psyence Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Psyence Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Psyence Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Psyence Biomedical is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Psyence Biomedical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Psyence Biomedical stock to make a market-neutral strategy. Peer analysis of Psyence Biomedical could also be used in its relative valuation, which is a method of valuing Psyence Biomedical by comparing valuation metrics with similar companies.
Peers
Psyence Biomedical Related Equities
| GNL-PD | Global Net | 1.97 | ||||
| FTAIM | FTAI Aviation | 1.21 | ||||
| WLFC | Willis Lease | 0.89 | ||||
| SPNT | Siriuspoint | 0.79 | ||||
| UNM | Unum | 0.70 | ||||
| LINSA | Life Insurance | 0.00 | ||||
| CFRLF | China Aircraft | 0.00 | ||||
| MIUFY | Mitsubishi UFJ | 4.80 |
Additional Tools for Psyence Stock Analysis
When running Psyence Biomedical's price analysis, check to measure Psyence Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Psyence Biomedical is operating at the current time. Most of Psyence Biomedical's value examination focuses on studying past and present price action to predict the probability of Psyence Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Psyence Biomedical's price. Additionally, you may evaluate how the addition of Psyence Biomedical to your portfolios can decrease your overall portfolio volatility.